Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FYN | P06241 | 18/20 | 0.67 |
| ▸ | IKBKB | O14920 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1053098 | 0.83 | FYN (0.77) | FYNKDM4ENPC1RAB9ASMN1; SMN2 | |
| SCHEMBL4694473 | 0.82 | FYN (0.63) | FYNIKBKB | |
| SCHEMBL19467148 | 0.81 | FYN (0.62) | FYNIKBKB | |
| SCHEMBL15254599 | 0.81 | MKNK1 (0.57) | FYNIKBKB | |
| SCHEMBL19467246 | 0.81 | IKBKB (0.52) | FYNIKBKB | |
| SCHEMBL2950405 | 0.80 | FYN (1.00) | FYN | |
| SCHEMBL15254715 | 0.80 | IKBKB (0.52) | FYNIKBKB | |
| SCHEMBL15254184 | 0.80 | FYN (0.55) | FYNIKBKB | |
| SCHEMBL4692424 | 0.80 | FYN (0.64) | FYNIKBKB | |
| SCHEMBL15254759 | 0.79 | IKBKB (0.53) | FYNIKBKB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1900739-A1 | Diazolodiazine derivatives as kinase inhibitors | CELLZOME AG (DE) | 2008-03-19 | — | — | EP | claimed |
| EP-1900739-A1 | Diazolodiazine derivatives as kinase inhibitors | CELLZOME AG (DE) | 2008-03-19 | — | — | EP | disclosed |
| WO-2007025090-A2 | HETEROBICYCLIC AND - TRICYCLIC INHIBITORS OF MAPK/ERK KINASE | KALYPSYS, INC. (US) | 2007-03-01 | — | — | WO | disclosed |
| US-20070049591-A1 | Inhibitors of MAPK/Erk Kinase | KALYPSYS, INC. | 2007-03-01 | — | — | US | disclosed |
| US-20070049591-A1 | Inhibitors of MAPK/Erk Kinase | KALYPSYS, INC. | 2007-03-01 | — | — | US | disclosed |
| US-20070049591-A1 | Inhibitors of MAPK/Erk Kinase | KALYPSYS, INC. | 2007-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070049591-A1 | Inhibitors of MAPK/Erk Kinase | MAPK1, MAP3K1, MAP3K6 | FYN 322/4885IKBKB 173/4885KDM4E 3209/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.